Key facts
- · What it is: Progress update · C-U
- · Intermediary: Dealmaker Securities LLC · Target: $11K · Maximum: $4.40M · Deadline: 2026-07-31 · Security: Common Stock · C/A
- · Intermediary: Dealmaker Securities LLC · Target: $11K · Maximum: $4.40M · Deadline: 2026-07-31 · Security: Common Stock · C/A
- · What it is: Annual report · C-AR
- · What it is: Annual report amended · C-AR/A
Fisher Wallace Laboratories, Inc., based in Brooklyn, NY, filed 10 Regulation Crowdfunding offering filings with the SEC, the latest on 2026-07-16, raising through Dealmaker Securities LLC. It set a target of $11K and will accept up to $4.40M. The security offered is common stock at $11.3 each. As of its filings the offering is past its deadline of 2026-07-31. 22 filings in this family are on record for the company.
Offering filings
| Filed | Intermediary | Target | Maximum | Deadline | Security | Filing |
|---|---|---|---|---|---|---|
| 2026-07-16 | Dealmaker Securities LLC | $11K | $4.40M | 2026-07-31 | Common Stock | C/A |
| 2026-05-22 | Dealmaker Securities LLC | $11K | $4.40M | 2026-07-31 | Common Stock | C/A |
| 2026-04-17 | Dealmaker Securities LLC | $11K | $4.40M | 2026-07-31 | Common Stock | C |
| 2026-01-30 | Dealmaker Securities LLC | $104K | $2.59M | 2026-02-20 | Common Stock | C |
| 2025-11-24 | Dealmaker Securities LLC | $104K | $2.59M | 2025-12-15 | Common Stock | C |
| 2025-10-02 | Dealmaker Securities LLC | $50K | $900K | 2025-10-22 | Common Stock | C |
| 2025-02-20 | Dealmaker Securities LLC | $10K | $518K | 2025-03-12 | Convertible Note | C |
| 2024-12-12 | Dealmaker Securities LLC | $10K | 2025-01-02 | Common Stock | C | |
| 2024-10-08 | Dealmaker Securities LLC | $10K | 2024-10-17 | Common Stock | C/A | |
| 2024-09-26 | Dealmaker Securities LLC | $10K | 2024-10-17 | Common Stock | C |
Want the whole picture on Fisher Wallace Laboratories, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Fisher Wallace Laboratories, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Fisher Wallace Laboratories, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
22 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Financials the company filed
Figures from the C-U filed 2026-09-21, as the company reported them.
| As filed | Most recent fiscal year | Prior fiscal year |
|---|---|---|
| Revenue | $34K | $47K |
| Net income | -$1.45M | -$1.58M |
| Total assets | $145K | $154K |
| Cash and equivalents | $48K | |
| Short-term debt | $591K | |
| Long-term debt | $694K |
Employees at filing: 3.
Progress updates
2026-09-21, C-U:
The Offering ended on September 16, 2026 having closed on funds totaling $433,143.48. However, final accounting has yet to take place.
2026-03-24, C-U:
The Offering ended on February 20, 2026, having closed on $130,120.23 with a total of 11,215 securities sold.
2026-03-04, C-U:
The Offering ended on February 20, 2026, having closed on $127,683.74 of funds although final accounting has yet to take place.
2026-01-20, C-U:
As of December 23, 2025, Fisher Wallace successfully closed on $195,452.00 of investments from 158 investors.
2025-11-06, C-U:
As of November 5, 2025, Fisher Wallace successfully closed on $228,289.74 of investments from 218 investors
People who signed the filing
- /Kelly Roman/, Chief Executive Officer and Director
Every filing
| Filed | What it is | Filing |
|---|---|---|
| 2026-09-21 | Progress update | C-U |
| 2026-07-16 | Offering amended | C/A |
| 2026-05-22 | Offering amended | C/A |
| 2026-04-30 | Annual report | C-AR |
| 2026-04-30 | Annual report amended | C-AR/A |
| 2026-04-17 | Offering | C |
| 2026-03-24 | Progress update | C-U |
| 2026-03-04 | Progress update | C-U |
| 2026-01-30 | Offering | C |
| 2026-01-20 | Progress update | C-U |
| 2025-11-24 | Offering | C |
| 2025-11-06 | Progress update | C-U |
| 2025-10-02 | Offering | C |
| 2025-05-01 | Annual report | C-AR |
| 2025-04-02 | Progress update | C-U |
| 2025-02-20 | Offering | C |
| 2025-01-31 | Progress update | C-U |
| 2024-12-12 | Offering | C |
| 2024-11-06 | Progress update | C-U |
| 2024-10-08 | Offering amended | C/A |
| 2024-09-26 | Offering | C |
| 2024-07-22 | Progress update | C-U |
A crowdfunding round is won in public. FoxPlug turns your commits, deploys and releases into the posts and visuals that keep the story moving while the offering is open.
Build your launch kitRun a Snapshot on /Kelly Roman/: other companies, roles and the record behind them. Order Full Report from there if you need more.
Snapshot the foundersTools for this story
Each opens in a new tab, filled in for Fisher Wallace Laboratories, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company raising money from the public under Regulation Crowdfunding has to file with the SEC before the offering opens, and has to raise through a single registered intermediary: a funding portal or a broker-dealer. The first filing, Form C, states how much the company is trying to raise, the most it will accept, the deadline, the security and its price, the intermediary and what the intermediary is paid, and two years of the company's own financial figures.
After that the company files amendments when terms change, progress updates as the raise moves, and an annual report each year until it stops reporting. Every row here is one of those filings, linked to the filing itself, so each figure can be checked at the source. Figures are exactly as the company filed them; where a filing leaves a field blank, so does this page. Nothing here is investment advice, and a filing is the company's own statement, not a verification of it.